Ma Ling-Yan, Han Lin, Niu Meng, Chen Lu, Yu Ya-Zhen, Feng Tao
Department of Neurology, Center for Movement Disorders, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
China National Clinical Research Center for Neurological Diseases, Beijing, China.
Front Neurol. 2022 May 30;13:865690. doi: 10.3389/fneur.2022.865690. eCollection 2022.
Paroxysmal kinesigenic dyskinesia (PKD) is a rare neurological disorder characterized by recurrent involuntary movements usually triggered by sudden movements. Mutations in the gene were found to be the causative factor of PKD in recent studies. It has also been revealed that loss-of-function is the mechanism by which mutations cause PKD.
To investigate the genetic basis of PKD and broaden the clinical spectrum of the mutations, we recruited 181 patients of Chinese origin with movement disorders (MDs), including 39 -negative PKD, 3 paroxysmal exercise-induced dyskinesia (PED), 2 paroxysmal non-kinesigenic dyskinesia (PNKD), 127 isolated dystonia, 8 choreas, and 2 myoclonus-dystonia syndromes. Whole-exome sequencing was applied to identify their possible disease-causing mutations. Then, Sanger sequencing was performed for validation and co-segregation analysis. Genetic analysis was also performed on additional family members of patients with mutations. Clinical manifestations of all PKD cases with mutations in reported, so far, were reviewed.
Two novel variants of the gene (NM_153266.4, NP_694998.1), c.627_643dup (p.A215Gfs53) and c.627delG (p.L210Wfs52), were identified in 2 patients with PKD by whole-exome sequencing and further Sanger sequencing. Both variants were inherited by the patients from their respective mothers. No mutation of the gene was found in the other type of movement disorders. In reviewing the clinical presentation of -related PKD, no statistically significant difference in the age of onset, family history, duration of attacks, laterality, and phenotype was found between genders. More male patients received treatment and had a good response. A higher proportion of female patients did not receive any treatment, possibly because they had a milder condition of the disease.
This study further validated the role of in PKD. Future studies on protein function will be needed to ascertain the pathogenesis of in PKD.
发作性运动诱发性运动障碍(PKD)是一种罕见的神经系统疾病,其特征为反复出现的不自主运动,通常由突然的动作触发。最近的研究发现该基因突变是PKD的致病因素。研究还表明,功能丧失是该基因突变导致PKD的机制。
为了研究PKD的遗传基础并拓宽该基因突变的临床谱,我们招募了181名有运动障碍(MD)的中国患者,包括39例基因阴性的PKD患者、3例发作性运动诱发性运动障碍(PED)患者、2例发作性非运动诱发性运动障碍(PNKD)患者、127例孤立性肌张力障碍患者、8例舞蹈病患者和2例肌阵挛性肌张力障碍综合征患者。应用全外显子测序来确定他们可能的致病突变。然后,进行Sanger测序以进行验证和共分离分析。还对该基因突变患者的其他家庭成员进行了基因分析。回顾了迄今为止报道的所有携带该基因突变的PKD病例的临床表现。
通过全外显子测序和进一步的Sanger测序,在2例PKD患者中鉴定出该基因(NM_153266.4,NP_694998.1)的两个新变异,即c.627_643dup(p.A215Gfs53)和c.627delG(p.L210Wfs52)。这两个变异均由患者从各自母亲处遗传而来。在其他类型的运动障碍中未发现该基因突变。在回顾与该基因相关的PKD的临床表现时,发现性别之间在发病年龄、家族史、发作持续时间、偏侧性和表型方面没有统计学上的显著差异。接受治疗且反应良好的男性患者更多。较高比例的女性患者未接受任何治疗,可能是因为她们的病情较轻。
本研究进一步验证了该基因在PKD中的作用。未来需要对蛋白质功能进行研究,以确定该基因在PKD中的发病机制。